Appeal No. 1997-1160
Application No. 08/036,566
Claim 24 is illustrative of the subject matter on appeal and is reproduced
below:
24. A dosage form for administering an anti-Parkinson drug to a patient, wherein
the dosage form comprises:
(a) a composition comprising 0.10 mg to 750 mg of an anti-Parkinson drug
and a pharmaceutically acceptable carrier for the anti-Parkinson drug selected
from the group consisting of hydroxypropylcellulose, hydroxypropylmethyl-cellulose
and polyvinylpyrrolidone, which composition in the presence of fluid that contacts
the dosage form provides a dispensable anti-Parkinson therapeutic formulation;
and wherein the dosage form:
(b) provides the anti-Parkinson drug substantially-free of adverse
effects for administration in a rate-controlled metered dose per unit time over
24 hours.
Claim 26 is directed to a method of management of paralysis agitans by
administering a drug composition that essentially parallels claim 24. Claims 25 and 27
depend from claims 24 and 26 respectively and add the limitation of a particular anti-
Parkinson drug selected from a Markush grouping which includes, inter alia, levodopa,
carbidopa, levodopa-carbidopa and trihexyphenidyl.
The reference relied upon by the examiner is:
Physicians’ Desk Reference (PDR), 43rd Edition, pp. 1110-111, 1390-391 (1989)
2
Page: Previous 1 2 3 4 5 6 Next
Last modified: November 3, 2007